Association of Mannan Binding Lectin to Liver Fibrosis in Chronic HCV Patients
Abstract
Full Text:
PDFReferences
Esmat S, Omran D, Sleem GA and Rashed L (2012): Serum Mannan-Binding Lectin in Egyptian Patients with Chronic Hepatitis C: Its Relation to Disease Progression and Response to Treatment. Hepat Mon.; 12(4):259-64.
EASL Clinical Practice Guidelines(2011): Management of hepatitis C virus infection, European Association for the Study of the Liver, Journal of Hepatology; 55(2):245–264.
Sarrazin C, Berg T and Ross R (2010): Prophylaxis, diagnosis and therapy of hepatitis C virus (HCV) infection: the German guidelines on the management of HCV infection. Z Gastroenterol; 48(2):289–351.
AlvesPedroso ML, Boldt ABW ,Pereira-Ferrari L ,Steffensen R, Strauss E , Jensenius JC, Ioshii SO , et al.(2008):Mannan-binding lectin MBL2 gene polymorphism in chronic hepatitis C: association with the severity of liver fibrosis and response to interferon therapy Journal compilation British Society for Immunology, Clinical and Experimental Immunology;152(2): 258–264.
Tarr AW, Urbanowicz RA and Ball JK (2012): The Role of Humoral Innate Immunity in Hepatitis C Virus Infection. Viruses;4(1):1-27.
Kilpatrick DC, Delahooke TE, Koch C, Turner ML, and Hayes PC(2003):Mannan-binding lectin and hepatitis C infection. ClinExpImmunol; 132(1): 92–95.
Jack DL and Turner MW(2003):Anti-microbial activities of mannose-binding lectin. BiochemSoc Trans; 31(4):753-7.
Franciscus A, 2010: HCV Diagnostic tools: Grading and staging a liver biopsy.HCSP;, Version 2.4.
Koutsounaki E, Goulielmos GN, Koulentaki M, Choulaki C, Kouroumalis E and Galanakis E (2008): Mannose-binding lectin MBL2 gene polymorphisms and outcome of hepatitis C virus infected patients. J ClinImmunol;28(5):495–500.
Ribeiro LZ ,Tripp RA, Rossi LM, Palma PV, Yokosawa J, Mantese OC, et al.(2008): Serum mannose-binding lectin levels are linked with respiratory syncytial virus (RSV) disease. J clinimmunol; 28(2):166-73
ElSaadanySA ,Ziada DH , Farrag W , Hazaa S (2011): .Fibrosis severity and mannan-binding lectin (MBL)/MBL-associated serine protease 1 (MASP-1) complex in HCV-infected patients Arab Journal of Gastroenterology; 12(2):68–73.
Liu J, Ali MA, Shi Y, Zhao Y, Luo F, Yu J, et al. (2009): Specifically binding of L-ficolin to N-glycans of HCV envelope glycoproteins E1 and E2 leads to complement activation. Cell Mol. Immunol.;6(4): 235–244.
Heidelbaugh JJ and Bruderly M (2006): Cirrhosis and Chronic Liver Failure: Part I. Diagnosis and Evaluation. American Family Physician; 74(5):756-62.
Ytting H, Christensen IJ, Thiel S, Jensenius JC, Svendsen MN, Nielsen L, et al. (2007):Biological variation in circulating levels of mannan-binding lectin (MBL) and MBL-associated serine protease-2 and the influence of age, gender and physical exercise. Scand J Immunol.;66(4):458-64.
Nadeem A, Hussain M, Aslam M, Hussain T, Butt IF, Ali Khan S, et al.(2009): Association of response to combined interferon alpha-2b and ribavirin therapy in patients of chronic hepatitis c with serum alanine aminotransferase levels and severity of the disease on liver biopsy. J Ayub Med Coll Abbottabad;21(2):103-6.
Derbala M, Al Kaabi S, El Dweik N , Pasic F, Butt MT, Yakoob R, et al. (2006):Treatment of hepatitis C virus genotype 4 with peginterferon alfa-2a: Impact of bilharziasis and fibrosis stage. World J Gastroenterol; 12(35):5692-5698.
Poynard T, McHutchison J, Davis G, Esteban-Mur R, Goodman Z, Bedossa P et al.(2000) :Impact of interferon alfa-2b and ribavirin on progression of liver fibrosis in patients with chronic hepatitis C. Hepatology; 32(5):1131–1137.
Manns M, McHutchison J, Gordon S,Rustgi VK, Shiffman M, Reindollar R, et al.(2001): Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomized trial. Lancet; 358(9286): 958-965.
Dienstag J (2002): The role of liver biopsy in chronic hepatitis C. Hepatology;36(1):152–60.
Bruno S, Shiffman M, Roberts S , Gane EJ, Messinger D, Hadziyannis SJ, et al.(2010): Efficacy and Safety of Peg interferon Alfa-2a (40KD) Plus Ribavirin in Hepatitis C Patients with Advanced Fibrosis and Cirrhosis. Hepatology; 51(2):388-397.
Refbacks
- There are currently no refbacks.